Discontinuation report MYOCHRYSINE
| Report ID | 86067 |
| Drug Identification Number | 01927620 |
| Brand name | MYOCHRYSINE |
| Common or Proper name | Myochrysine 10 mg |
| Company Name | SANOFI-AVENTIS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | GOLD SODIUM THIOMALATE |
| Strength(s) | 10MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Packaging size | 5 ampoules |
| ATC code | M01CB |
| ATC description | SPECIFIC ANTIRHEUMATIC AGENTS |
| Reason for discontinuation | Other (Please describe in comments) |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2019-06-04 |
| Remaining supply date | 2018-04-04 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | email: [email protected] Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2019-06-10 | French | Compare |
| v1 | 2019-06-10 | English | Compare |
Showing 1 to 2 of 2